Update on Flat and Papillary Urothelial Lesions: Genitourinary Pathology Society Consensus Recommendations.

[1]  A. Masson-Lecomte,et al.  European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ). , 2021, European urology.

[2]  J. Cheville,et al.  The Genitourinary Pathology Society Update on Classification and Grading of Flat and Papillary Urothelial Neoplasia With New Reporting Recommendations and Approach to Lesions With Mixed and Early Patterns of Neoplasia , 2021, Advances in anatomic pathology.

[3]  O. İpek,et al.  Adenocarcinoma in Orthotopic Neobladder 19 Years After Radical Cystoprostatectomy. , 2021, Journal of the College of Physicians and Surgeons--Pakistan : JCPSP.

[4]  T. H. van der Kwast,et al.  International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. , 2021, European urology focus.

[5]  L. Kiemeney,et al.  European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. , 2021, European urology.

[6]  O. Cussenot,et al.  A four-antibody immunohistochemical panel can distinguish clinico-pathological clusters of urothelial carcinoma and reveals high concordance between primary tumor and lymph node metastases , 2020, Virchows Archiv.

[7]  E. Compérat,et al.  Molecular Genetic Features of Primary Nonurachal Enteric-type Adenocarcinoma, Urachal Adenocarcinoma, Mucinous Adenocarcinoma, and Intestinal Metaplasia/Adenoma: Review of the Literature and Next-generation Sequencing Study , 2020, Advances in anatomic pathology.

[8]  M. Amin,et al.  CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia , 2020, Diagnostic Pathology.

[9]  J. Witjes,et al.  European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. , 2020, European urology.

[10]  V. Reuter,et al.  Inverted urothelial papilloma and urothelial carcinoma with inverted growth are histologically and molecularly distinct entities , 2020, The Journal of pathology.

[11]  D. Sahoo,et al.  Urothelial Proliferation of Unknown Malignant Potential Involving the Bladder: Histopathologic Features and Risk of Progression in De Novo Cases and Cases With Prior Neoplasia. , 2019, Archives of pathology & laboratory medicine.

[12]  B. Delahunt,et al.  Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. , 2019, European urology.

[13]  A. Sangoi,et al.  Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases. , 2019, The American journal of surgical pathology.

[14]  V. Reuter,et al.  Reply re: Murali Varma, Brett Delahunt, Theodorus van der Kwast. Grading Noninvasive Bladder Cancer: World Health Organisation 1973 or 2004 May Be the Wrong Question. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.05.001: Two Decades of World Health Organisation/International Society of U , 2019, European urology.

[15]  A. Lopez‐Beltran,et al.  Predicting outcomes in non-muscle invasive (Ta/T1) bladder cancer: the role of molecular grade based on luminal/basal phenotype , 2019, Virchows Archiv.

[16]  J. Raman,et al.  Maintenance of the bladder cancer precursor urothelial hyperplasia requires FOXA1 and persistent expression of oncogenic HRAS , 2019, Scientific Reports.

[17]  J. McKenney.  Precursor lesions of the urinary bladder , 2019, Histopathology.

[18]  M. Babjuk,et al.  Prognostic Performance and Reproducibility of the 1973 and 2004/2016 World Health Organization Grading Classification Systems in Non-muscle-invasive Bladder Cancer: A European Association of Urology Non-muscle Invasive Bladder Cancer Guidelines Panel Systematic Review. , 2017, European urology.

[19]  M. Tretiakova,et al.  Stalk versus base invasion in pT1 papillary cancers of the bladder: improved substaging system predicting the risk of progression , 2017, Histopathology.

[20]  I. Kulac,et al.  The Influence of Inverted Growth Pattern on Recurrence for Patients with Non-Invasive Low Grade Papillary Urothelial Carcinoma of Bladder , 2017, Balkan medical journal.

[21]  T. Kwast,et al.  Analysis of papillary urothelial carcinomas of the bladder with grade heterogeneity: supportive evidence for an early role of CDKN2A deletions in the FGFR3 pathway , 2017, Histopathology.

[22]  Holger Moch,et al.  The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours. , 2016, European urology.

[23]  R. Knüchel-Clarke,et al.  Präneoplastische Läsionen und Vorstufen des Urothelkarzinoms , 2016, Der Pathologe.

[24]  J. Cheville,et al.  Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer , 2015, Modern Pathology.

[25]  K. Trpkov,et al.  Long-term outcome of primary Papillary Urothelial Neoplasm of Low Malignant Potential (PUNLMP) including PUNLMP with inverted growth , 2015, Diagnostic Pathology.

[26]  O. Cussenot,et al.  Clinicopathological characteristics of urothelial bladder cancer in patients less than 40 years old , 2015, Virchows Archiv.

[27]  G. Hidas,et al.  Mixed high and low grade bladder tumors--are they clinically high or low grade? , 2014, The Journal of urology.

[28]  J. Epstein,et al.  Invasive Low-Grade Papillary Urothelial Carcinoma: A Clinicopathologic Analysis of 41 Cases , 2012, The American journal of surgical pathology.

[29]  C. Pan,et al.  Constructing prognostic model incorporating the 2004 WHO/ISUP classification for patients with non-muscle-invasive urothelial tumours of the urinary bladder , 2010, Journal of Clinical Pathology.

[30]  A. Krasinskas,et al.  Tubular adenoma with high-grade dysplasia in the ileal segment 34 years after augmentation ileocystoplasty: report of a first case , 2007, Diagnostic pathology.

[31]  V. Paradis,et al.  Aurora-A/STK-15 is a predictive factor for recurrent behaviour in non-invasive bladder carcinoma: a study of 128 cases of non-invasive neoplasms , 2007, Virchows Archiv.

[32]  T. H. van der Kwast,et al.  Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder , 2006, International journal of cancer.

[33]  R Y Ball,et al.  Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs , 2005 .

[34]  R. Knuechel,et al.  Frequent genetic alterations in flat urothelial hyperplasias and concomitant papillary bladder cancer as detected by CGH, LOH, and FISH analyses , 2003, The Journal of pathology.

[35]  B. Loftus,et al.  Keratinising squamous metaplasia of the bladder: natural history and rationalization of management based on review of 54 years experience. , 2002, European urology.

[36]  J. McKenney,et al.  Morphologic Expressions of Urothelial Carcinoma In Situ: A Detailed Evaluation of Its Histologic Patterns With Emphasis on Carcinoma In Situ With Microinvasion , 2001, The American journal of surgical pathology.

[37]  T. H. van der Kwast,et al.  Preneoplastic non-papillary lesions and conditions of the urinary bladder: an update based on the Ancona International Consultation , 2001, Virchows Archiv.

[38]  D. Bostwick,et al.  Predicting the survival of bladder carcinoma patients treated with radical cystectomy , 2000, Cancer.

[39]  Lawrence D. True,et al.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder , 1998 .